Follow-Up of the Patient with an Implanted Cardiac Defibrillator

  • Ejigayehu Abate
  • Fred M. Kusumoto

Since the initial development of the implantable defibrillator in the 1970s by Michel Mirowski, and commercial introduction in 1985, national surveys and industry analysts have estimated that more than 160,000 implants have been performed in the United States (1). Multicenter randomized trials have demonstrated the effectiveness of the implantable cardioverter-defibrillator (ICD) for reducing mortality in high-risk patient groups (2,3). It has been estimated that more than 700,000 patients are eligible for an ICD in the United States. The newest generation of ICDs are capable of defibrillation of ventricular fibrillation, pace termination of ventricular tachycardia, single or dual chamber pacing, and cardiac resynchronization therapy (CRT) depending on the model. In addition, ICDs now have multiple additional features including extensive programming options, detailed event histories, and real-time telemetry.


Ventricular Tachycardia Ventricular Fibrillation Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillator Implantable Defibrillator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bernstein AD, and Parsonnet V. Survey of cardiac pacing and defibrillation in the United States in 1993. Am J Cardiol 1996;78:187–196.CrossRefPubMedGoogle Scholar
  2. 2.
    Moss A, Zareba W, Hall W, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, and Andrew ML. Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection faction. N Eng J Med. 2002;346:877–883.CrossRefGoogle Scholar
  3. 3.
    The AVID investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583.CrossRefGoogle Scholar
  4. 4.
    Kadish A, Dyer A, Daubert J, Quigg R, Estes M, Anderson KP, Clarkins H, Hoch D, Goldberger J, Shalaby A, Sanders W, Schaechter A, and Levine J. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Eng J Med 2004;350:2151–2158.CrossRefGoogle Scholar
  5. 5.
    Rosenqvist M, Beyer T, Block M, Dulk KD, Minten J, and Lindemans F. Adverse events with transvenous implantable cardioverterdefibrillators: a prospective multicenter study. Circulation 1998;98:663–670.PubMedGoogle Scholar
  6. 6.
    Lehmann MH, Thomas A, Nabih M, Steinman RT, Fromm BS, Shah M, and Norsted SW. Sudden death in recipients of first generation implantable cardioverter defibrillators: analysis of terminal events. J Interventional Cardiol 1994;7:487–503.CrossRefGoogle Scholar
  7. 7.
    Chevalier P, Moncada E, Canu G, Claudel JP, Bellon C, Kirkorian G, and Touboul P. Symptomatic pericardial disease associated with patch electrodes of the automatic implantable cardioverter defibrillator: an underestimated complication? Pacing Clin Electrophysiol 1996;19:2150–2152.CrossRefPubMedGoogle Scholar
  8. 8.
    Hegel MT, Griegel LE, Black C, Goulden L, and Ozahowski T. Anxiety and depression in patients receiving implanted cardioverter defibrillators: a longitudinal investigation. Int J Psychiatry Med 1997;27:27–69.Google Scholar
  9. 9.
    Crow SJ, Collins J, Justic M, Goetz R, and Adler S. Psychopathology following cardioverter defibrillator implantation. Psychosomatics 1998;39:305–310.PubMedGoogle Scholar
  10. 10.
    Heller SS, Ormont MA, Lidagoster L, Sciacca RR, and Steinberg S. Psychosocial outcome after ICD implantation: a current perspective. Pacing Clin Electrophysiol 1998;21:1207–1215.CrossRefPubMedGoogle Scholar
  11. 11.
    Hammel D, Scheld HH, Block M, and Breithardt G. Nonthoracotomy defibrillator implantation: a single-center experience with 200 patients. Ann Thorac Surg 1994;58:321–327.PubMedCrossRefGoogle Scholar
  12. 12.
    Schwartzman D, Nallamothu N, Callans DJ, Preminger MW, Gottlieb CD, and Marchlinski FE. Postoperative lead-related complications in patients with nonthoracotomy defibrillation lead systems. J Am Coll Cardiol 1995;26:776–786.CrossRefPubMedGoogle Scholar
  13. 13.
    Robinson LA, Windle JR. Defibrillator twiddler’s syndrome. Ann Thorac Surg 1994;58:247–249.PubMedGoogle Scholar
  14. 14.
    Korte T, Jung W, Schlippert U, Wolpert C, Esmailzadeh B, Fimmers R, Schmitt O, and Luderitz B. Prospective evaluation of shoulder-related problems in patients with pectoral cardioverter-defibrillator implantation. Am Heart J 1998;135:577–583.CrossRefPubMedGoogle Scholar
  15. 15.
    Brady PA, Friedman PA, and Trusty JM. High failure rate for an epicardial implantable cardioverterdefibrillator lead: implications for long-term follow-up of patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31:616–621.CrossRefPubMedGoogle Scholar
  16. 16.
    Gupta A, Zegel HG, and Dravid VS. Value of radiography in diagnosing complications of cardioverter defibrillators implanted without thoracotomy in 437 patients. Am J Roentgenol 1997;168:105–108.Google Scholar
  17. 17.
    Drucker EA, Brooks R, Garan H, Sweeney MO, Ruskin JM, McGovern BA, and Miller SW. Malfunction of implantable cardioverter defibrillators placed by a nonthoractomy approach: frequency of malfunction and value of chest radiography in determining cause. Am J Roentgenol 1995;165:275–279.Google Scholar
  18. 18.
    Nathan AW. The role of cardioversion therapy in patients with implanted cardioverter defibrillators. Am Heart J 1994;127(4 Pt 2):1046–1051.CrossRefPubMedGoogle Scholar
  19. 19.
    Barold SS, Newby KH, Tomassoni G, Kearney M, Brandon J, and Natale A. Prospective evaluation of new and old criteria to discriminate between supraventricular and ventricular tachycardia in implantable defibrillators. Pacing Clin Electrophysiol 1998;21:1347–1355.CrossRefPubMedGoogle Scholar
  20. 20.
    Swerdlow CD, Chen PS, Kass RM, Allard JR, and Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol 1994;23:1342–1355.PubMedGoogle Scholar
  21. 21.
    Klingenheben T, Sticherling C, Skupkin M, and Hohnloser SH. Intracardiac QRS electrogram width: an arrhythmia detection feature for implantable cardioverter defibrillators: exercise included variation as a base for device programming. Pacing Clin Electrophysiol 1998;21:1609–1617.CrossRefPubMedGoogle Scholar
  22. 22.
    Favale S, Nacci F, Galati A, Accogli M, De Giorgi V, Greco MR, Nastasi M, Pierfelice O, Rossi S, and Gargaro A. Electrogram width parameter analysis in implantable cardioverter defibrillators: influence of body position and electrode configuration. Pacing Clin Electrophysiol 2001;24:1732–1738.CrossRefPubMedGoogle Scholar
  23. 23.
    Theuns DAMJ, Rivero-Ayerza M, Goedhart DM, van der Perk R, and Jordaens LJ. Evalution of morphology discrimination for ventricular tachycardia diagnosis in implantable cardioverter-defibrillators. Heart Rhythm 2006;3:1332–1338.CrossRefPubMedGoogle Scholar
  24. 24.
    Soundarraj D, Thakur RK, Gardiner JC, Khasnis A, and Jongnaransin K. Inappropriate ICD therapy: does device configuration make a difference? Pacing Clin Electrophysiol 2006;29:810–815.CrossRefPubMedGoogle Scholar
  25. 25.
    Theuns DAMJ, Klootwijk APJ, Goedhart DM, and Jordaens LJ. Prevention of inappropriate therapy in implantable cadioverter defibrillators. Results of a prospective, randomized study of tachyarrhythmia detection algorithms. J Am Coll Cardiol 2004;44:2362–2367.CrossRefPubMedGoogle Scholar
  26. 26.
    Purerfellner H, Gillis AM, Holbrook R, and Hettrick DA. Accuracy of atrial tachyarrhythmiadetection in implantable devices with arrhythmia therapies. Pacing Clin Electrophysiol 2004;27:983–992.CrossRefPubMedGoogle Scholar
  27. 27.
    Friedman PA, McClelland RL, Bmlet WR, Acosta H, Kessler D, Munger TM, Kavesh NG, Wood M, Daoud E, Massumi A, Schuger C, Shorofsky S, Wilkoff B, and Glikson M. Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis. The detect supraventricular tachycardia study. Circulation 2006;113:2871–2879.CrossRefPubMedGoogle Scholar
  28. 28.
    Marchlinski FE, Flores B, Miller JM, Gottlieb CD, and Hargrove WC 3rd. Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implantable cardioverter defibrillator. Am J Cardiol 1988;62:393–398.CrossRefPubMedGoogle Scholar
  29. 29.
    Neuzner J. Safety margins: lessions from the low energy Endotak trial (LEET). Am J Cardiol 1996;78(5A):26–32.CrossRefPubMedGoogle Scholar
  30. 30.
    Nasir N, Pacifico A, Doyle TK, Earle NR, Hardage ML, and Henry PD. Spontaneous ventricular tachycardia treated by antitachycardia pacing. Am J Cardiol 1997;79:820–822.CrossRefPubMedGoogle Scholar
  31. 31.
    Ruppel R, Schluter CA, Boczar S, Meinertz T, Schluter M, Kuck KH, and Cappato R. Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: experience from stored electrograms of implantable cardioverter-defibrillators. J Am Coll Cardiol 1998;32:1724–1730.CrossRefPubMedGoogle Scholar
  32. 32.
    Grimm W, Plachta E, Maisch B. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy. Pacing Clin Electrophysiol 2006;29:759–764.CrossRefPubMedGoogle Scholar
  33. 33.
    Olatidoye AG, Verroneau J, and Kluger J. Mechanisms of syncope in implantable cardioverter-defibrillator recipients who receive device therapies. Am J Cardiol 1998;82:1372–1376.CrossRefPubMedGoogle Scholar
  34. 34.
    Schaumann A, von zur Muhlen F, Herse B, Gonska BD, and Kreuzer H. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators. A prospective study including 200 patients. Circulation 1998;97:66–74.PubMedGoogle Scholar
  35. 35.
    Jimenez-Candil J, Arenal A, Garcia-Alberola A, Ortiz M, del Castillo S, Fernandez-Portales J, Sanchez-Munoz J, Martinez-Sanchez J, Gonzalez-Torrecilla E, Atienza F, Puchol A, and Almendral J. Fast ventricular tachycardias in patients with implantable cardioverter-defibrillators: efficacy and safety of antitachycardia pacing. A randomized prospective study. J Am Coll Cardiol 2005;45:460–461.CrossRefPubMedGoogle Scholar
  36. 36.
    Wathen MS, Sweeney MO, DeGroot P, Stark AJ, Koehler JL, Chisner MB, Machado C, and Adkisson WO, for the PainFREE Rx Investigators. Shock reduction using antitachycardia pacing for spontaneous ventricular tachycardia in patients with coronary artery disease. Circulation 2001;104:796–801.CrossRefPubMedGoogle Scholar
  37. 37.
    Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, Khalighi K, Machado C, Rubenstein DS, and Volosin JK, for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empiric antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators. Pain FREE Rx II trial results. Circulation 2004;110:2592–2596.CrossRefGoogle Scholar
  38. 38.
    Laborderie J, Bordachar P, O’neill MD, and Clementy J. Fluctuation of atrial and ventricular lead impedances heralding subtotal separation of device header and generator in a patient with an implantable cardioverter-defibrillator. Heart Rhythm. 2007 Feb;4(2):218–220.CrossRefPubMedGoogle Scholar
  39. 39.
    Epstein AE, Plumb VJ, Kirkk KA, and Kay GN. Pacing threshold increase in nonthoractomy implantable defibrillator leads: implications for battery longevity and margin of safety. J Int Cardiac Electrophysiol 1997;1:131–134.CrossRefGoogle Scholar
  40. 40.
    Steinberg JS, Fischer A, Wang P, Schuger C, Daubert J, McNitt S, Andrews M, Brown M, Hall WJ, Zareba W, and Moss AJ; MADIT II Investigators. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol. 2005 Apr;16(4):359–365.PubMedGoogle Scholar
  41. 41.
    Sharma AD, Rizo-Patron C, Hallstrom AP, O’Neill GP, Rothbart S, Martins JB, Roelke M, Steinberg JS, and Greene HL; DAVID Investigators. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005 Aug;2(8):830–834.CrossRefPubMedGoogle Scholar
  42. 42.
    Gilliam FR, Kaplan AJ, Black J, Chase KJ, Mullin CM. Changes in Heart Rate Variability, quality of life, and activity in cardiac resynchronization therapy: Results of the HF-HRV Registry. Pacing Clin Electrophysiol 2007;30:56–64.CrossRefPubMedGoogle Scholar
  43. 43.
    Kadhiresen VA, Pastore J, Auricchio A, Sack S, Doelger A, Girouard S, and Spinelli JC. A novel method-the activity log index- for monitoring physical activity of patients with heart failure. Am J cardiol 2002;89:1435–1437.CrossRefGoogle Scholar
  44. 44.
    Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, and Lau CP. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112:841–848.CrossRefPubMedGoogle Scholar
  45. 45.
    Ypenburg C, Bax JJ, van der Wall EE, Schalij MJ, and van Erven L. Intrathoracic impedance monitoring to predict decompensated heart faiure. Am J Cardiol 2007;99:554–557.CrossRefPubMedGoogle Scholar
  46. 46.
    Mickelsen S, and Kusumoto FM. Balancing quality and thoroughness with efficiency in invasive cardiac electrophysiology. Cardiac Electrophysiol Rev 2000;4:133–136.CrossRefGoogle Scholar
  47. 47.
    Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL, Gibbons RJ, Antman EM, Alpert JS, Gregoratos G, Hiratzka LF, Faxon DP, Jacobs AK, Fuster V, and Smith SCJ. ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidlines). Circulation 2002;106:2145–2161.CrossRefPubMedGoogle Scholar
  48. 48.
    Winters SL, Packer DL, Marchlinski FE, Lazzara R, Cannom DS, Breithardt GE, Wilber DA, Camm AJ, and Ruskin JN. NASPE policy statement. Consensus statement on indications, guidelines for use, and recommendations for follow-up of implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2001;24:262–269.CrossRefPubMedGoogle Scholar
  49. 49.
    Rashba EJ, Olsovsky MR, Shorofsky SR, Kirk MM, Peters RW, and Gold MR. Temporal decline in defibrillation thresholds with an active pectoal lead system. J Am Coll Cardiol 2001;38:1150–1155.CrossRefPubMedGoogle Scholar
  50. 50.
    Venditti FJ, Martin DT, Vassolas G, and Bowen S. Rise in chronic defibrillation thresholds in nonthoractomy implantable defibrillator. Circulation 1994;89: 216–223.PubMedGoogle Scholar
  51. 51.
    Schwartzman D, Callans DJ, Gottlieb CD, Heo J, and Marchlinski FE. Early postoperative rise in defibrillation threshold in patients with nonthoracotomy defibrillation lead systems: attenuation with biphasic shock waveforms. J Cardiovasc Electrophysiol 1996;7:483–493.CrossRefPubMedGoogle Scholar
  52. 52.
    Olsovsky MR, Pelini MA, Shorofsky SR, and Gold MR. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol 1998;9:240–244.CrossRefPubMedGoogle Scholar
  53. 53.
    Gold MR, Khalighi K, Kavesh NG, Daly B, Peters RW, and Shorofsky SR. Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol 1997;79:1623–1627.CrossRefPubMedGoogle Scholar
  54. 54.
    Tokano T, Pelosi F, Flemming M, Horwood L, Souza JJ, Zivin A, Knight BP, Goyal R, Man KC, Morady F, and Strickberger SA. Long-term evaluation of ventricular defibrillation energy requirement. J Cardiovasc Electrophysiol 1998;9:916–920.CrossRefPubMedGoogle Scholar
  55. 55.
    Epstein AE, Kay GN, Plumb VJ, Dailey SM, and Anderson PG. Gross and microscopic pathological changes associated with nonthoracotomy implantable defibrillator leads. Circulation 1998;98:1517–1524.PubMedGoogle Scholar
  56. 56.
    Mehta D, Nayak HM, Singson M, Chao S, Pe E, Camunas JL, and Gomes JA. Late complications in patients with pectoral defibrillator implants with transvenous defibrillator lead systems: high incidence of insulation breakdown. Pacing Clin Electrophysiol. 1998;21:1893–1900.CrossRefPubMedGoogle Scholar
  57. 57.
    Hauser RG, Cannom D, Hayes DL, Parsonnet V, Hayes J, Ratliff N 3rd, Epstein AE, Vlay SC, Furman S, Gross J. Long-term structural failure of coaxial polyurethane implantable cardioverter defibrillator leads. Pacing Clin Electrophysiol 2002;57:879–882.CrossRefGoogle Scholar
  58. 58.
    Lawton JS, Wood MA, Gilligan DM, Stambler BS, Damiano RJ, Jr, and Ellenbogen KA. Implantable transvenous cardioverter defibrillator leads: the dark side. Pacing Clin Electrophysiol. 1996;19:1273–1278.CrossRefPubMedGoogle Scholar
  59. 59.
    Zilo P, Weiss DN, and Luceri RM. Late retesting of system performance in ICD patients without spontaneous shocks. Pacing Clin Electrophysiol. 1996;22:197–201.CrossRefGoogle Scholar
  60. 60.
    Stanton MS. Follow-up of implantable cardioverter-defibrillator patients. ACC Curr J Rev 1995;4:35–37.CrossRefGoogle Scholar
  61. 61.
    Bindra PS, Ruskin JN, and Keane D. Usefulness of predischarge defibrillation testing after defibrillator implantation in hospitalized patients. Am J Cardiol 2002;90:798–799.CrossRefPubMedGoogle Scholar
  62. 62.
    Delvecchio A, Trivedia HA, Fisher JD, KimSG, Ferrick KJ, Gross JN, and Palma EC. Value of pre-hospital discharge defibrillation testing in recipients of implantable cardioverter defibrillatos; Pacing Clin Electrophysiol 2005;28:S260–S262.CrossRefGoogle Scholar
  63. 63.
    Lurie KG, Iskos D, Fetter J, Peterson CA, Collins JM, Shultz JJ, Fahy GI, Sakaguchi S, and Benditt DG. Prehospital discharge defibrillation testing in ICD recipients: a prospective study based on cost analysis. Pacing Clin Electrophysiol 1999;22:192–196.CrossRefPubMedGoogle Scholar
  64. 64.
    Goldberger JJ, Horvath G, Inbar S, and Kadish AH. Utility of predischarge and one-month transvenous implantable defibrillator tests. Am J Cardiol 1997;79:822–826.CrossRefPubMedGoogle Scholar
  65. 65.
    Higgins SL, Rich DH, Haygood JR, Barone J, Greer SL, and Meyer DB. ICD restudy: results and potential benefit from routine pre-discharge and 2-month evaluation. Pacing Clin Electrophysiol. 1998;21:410–417.CrossRefPubMedGoogle Scholar
  66. 66.
    Stanton MS, and Bell GK. Economic outcomes of implantable cardioverter defibrillators. Circulation 2000;101:1067–1074.PubMedGoogle Scholar
  67. 67.
    Stepheson EA, Cecchin F, Walsh EP, and Berul CI. Utility of routine follow-up defibrillator threshold testing in congenial heart disease and pediatric populations. J Cardiovasc Electrophysiol 2005;16:69–73.CrossRefGoogle Scholar
  68. 68.
    Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, and Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006;114:104–109.CrossRefPubMedGoogle Scholar
  69. 69.
    Kusumoto FM, and Goldschlager N. Cost-effective follow-up of pacing systems. Electrophysiol Board Rev 1999 (in press).Google Scholar
  70. 70.
    Fetter JG, Stanton MS, Benditt DG, Trusty J, and Collins J. Transtelephonic monitoring and transmission of stored arrhythmia detection and therapy data from an implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 1995;18:1531–1539.CrossRefPubMedGoogle Scholar
  71. 71.
    Brugada P. What evidence do we have to replace in-hospital implantable cardioverter defibrillator follow-up? Clin Res Cardiol 2006;95(Suppl 3):III/3–9.CrossRefGoogle Scholar
  72. 72.
    Epstein AE, Baessler CA, Curtis AB, Estes NA 3rd, Gersh BJ, Grubb B, and Mitchell LB. Addendum to “Personal and public safety issues related to arrhythmias that may affect consciouness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology”. Public safety issues in patients with implantable defibrillators. A scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation. 2007 Feb 7.Google Scholar
  73. 73.
    Akiyama T, Powell JL, Mitchell LB, Baessler C. Antiarrhythmics versus Implantable Defibrillators Investigators. Resumption of driving after life-threatening ventricular tachyarrhythmia. N Engl J Med. 2001 Aug 9;345(6):391–397.CrossRefPubMedGoogle Scholar
  74. 74.
    Blumenthal R, Braunstein J, Connolly H, Epstein A, Gersh BJ, and Wittels EH. Cardiovascular advisory panel guidelines for medical examination of commercial motor vehicles drivers. FMCSA-MCP-02–2002. Washington DC: US Department of Transportation, Federal Motor Carrier Safety Administration FMCSA-MCP-02–2002; October 2002.Google Scholar
  75. 75.
    Rosenthal ME, and Paskman C. Noise detection during bradycardia pacing with a hybrid nonthoracotomy implantable cardioverter defibrillator system: incidence and clinical significance. Pacing Clin Electrophysiol 1998;21:1380–1386.CrossRefPubMedGoogle Scholar
  76. 76.
    Seifert T, Block M, Borgreffe M, and Breithardt G. Erroneous discharge of an implantable cardioverter defibrillator caused by an electric razor. Pacing Clin Electrophysiol 1995;18:1592–1594.CrossRefPubMedGoogle Scholar
  77. 77.
    Mclvor ME, Reddinger J, Floden E, and Sheppard RC. Study of pacemaker and implantable cardioverter defibrillator triggering by electronic article surveillance devices (SPICED TEAS). Pacing Clin Electrophysiol 1998;21:1847–1861.CrossRefGoogle Scholar
  78. 78.
    Kadish A, Dryer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Saundes WE, Schaechter A, and Levine JH: Defibrillators in nonischemiccardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator in patients with nonischemic dilated cardiomyopathy. New Engl J Med 2004;350:2151–2158.CrossRefPubMedGoogle Scholar
  79. 79.
    Messali A, Tomas O, Chauvin M, Coumel P, and Leenhardt A. Death due to an implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2004;15:953–956.PubMedGoogle Scholar
  80. 80.
    Prudente LA, Reigle J, Bourguignon C, Haines DE, and DiMarco JP. Psychological indices and phantom shocks in patients with ICD. J Interv Card Electrophysiol 2006;15:185–190.CrossRefPubMedGoogle Scholar
  81. 81.
    Kelly PA, Mann DE, Damle RS, and Reiter MJ. Oversensing during ventricular pacing in patients with a third-generation implantable cardioverter defibrillator. J Am Coll Cardiol 1994;23:1531–1534.PubMedCrossRefGoogle Scholar
  82. 82.
    Nunain SO, Roelke M, Trouton T, Osswalds S, Kim YH, Sosa-Suarez G, Brooks DR, McGovern B, Guy RN, Torchiana DF, Vlahakes GJ, Garan H, and Ruskin JN. Limitations and late complications of third generation automatic cardioverter-defibrillators. Circulation 1995;91:2204–2213.PubMedGoogle Scholar
  83. 83.
    Fogoros R, Elson J, and Bonnet C. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic cardioverter defibrillator. Pacing Clin Electrophysiol 1989;11:2014.Google Scholar
  84. 84.
    Credner SC, Klingenheben T, Mauss O, Sticherling C, and Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverter defibrillators: incidence, management, and prognostic implications. J Am Coll Cardiol 1998;32:1909–1915.CrossRefPubMedGoogle Scholar
  85. 85.
    Mann DE, Kelly PA, Damle RS, and Reiter MJ. Undersensing during ventricular tachyarrhythmias in a third generation implantable defibrillator: diagnosis using stored electrograms and correction with programming. Pacing Clin Electrophysiol.1994;17:1525–1530.CrossRefPubMedGoogle Scholar
  86. 86.
    Swerdlow CD, Ahern T, Chen PS, Hwang C, Gang E, Mandel W, Kass Rm, and Peter CT. Underdetection of ventricular tachycardia by algorithms to enhance specificity in a tiered therapy cardioverter-defibrillator. J Am Coll Cadiol 1994;24:416–424.CrossRefGoogle Scholar
  87. 87.
    Jung W, Manz M, Moosdorf R, Tebbenjohanns J, Pfeiffer D, and Luderitz B. Changes in the amplitude of endocardial electrograms following defibrillator discharge: comparison of two lead systems. Pacing Clin electrophysiol 1995;18:2163–2172.CrossRefPubMedGoogle Scholar
  88. 88.
    Berul CI, Callans DJ, and Schwartzman DS, et al. Comparison of initial detection and redetection of ventricular fibrillation in a transvenous defibrillator system with automatic gain control. J Am Coll Cardiol 1995;25:431–436.CrossRefPubMedGoogle Scholar
  89. 89.
    Herre JM, USA Endotak Investigators. Detection and redetection characteristics of the Endotak C transvenous lead system.Google Scholar
  90. 90.
    Goldberger JJ, Horvath G, Donovan D, Johnson D, Challapalli R, and Kadish AH. Detection of ventricular fibrillation by transvenous defibrillating leads: integrated versus dedicated bipolar sensing. J Cardiovasc Electrophysiol 1998;9:677–688.CrossRefPubMedGoogle Scholar
  91. 91.
    Stevenson WG, Friedman PL, Kucovic D, Sager PT, Saxon LA, and Pavri B. Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation 1998;98:308–314.PubMedGoogle Scholar
  92. 92.
    Rothman SA, Hsia HH, Cossu SF, Chmielewski IL, Buxton AE, Miller JM. Radiofrequency catheter ablation of postinfarction ventricular tachycardia: long-term success and the significance of inducible non-clinical arrhythmias. Circulation 1997;96:3499–3508.PubMedGoogle Scholar
  93. 93.
    Villacastin J, Almendral J, Arenal A, Albertos J, Ormaetxe J, Peinado R, Bueno H, Merino JL, Pastor A, Medina O, Tercedor L, Jimenez F, and Delcan JL. Incidence and clinical significance of multiple consecutive, appropriate, high-energy discharges in patients with implanted cardioverter defibrillators. Circulation 1996;93:753–762.PubMedGoogle Scholar
  94. 94.
    Kowey PR. An overview of antiarrhythmic drug management of electrical storm. Can J Cardiol 1996;12 (Suppl B):3B–8B.PubMedGoogle Scholar
  95. 95.
    Gornick CC, Hauser RG, Almquist AK, and Maron BJ. Unpredictable implantable cardioverter-defibrillator pulse generator failure due to electrical overstress causing sudden death in a young high-risk patient with hypertrophic cardiomyopathy. Heart Rhythm 2005;2:681–683.CrossRefPubMedGoogle Scholar
  96. 96.
    Maisel WH. Pacemaker and ICD generator reliability meta-analysis of device registries. JAMA 2006;295:1929–1934.CrossRefPubMedGoogle Scholar
  97. 97.
    Gould PA, and Krahn AD for the Canadian Heart Rhythm Society Working Group on Device Advisories. JAMA 2006;295:1907–1911.CrossRefPubMedGoogle Scholar
  98. 98.
    Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines. Heart Rhythm 2006;3:1250–1273.Google Scholar
  99. 99.
    Hauser RG, Hayes DL, Epstein AE, Cannom DS, Vlay SC, Song SL, and Tyers FO. Multicenter experience with failed and recalled implantable cardioverter-defibrillator pulse generators. Heart Rhythm 2006;3:640–644.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ejigayehu Abate
    • 1
  • Fred M. Kusumoto
    • 1
  1. 1.Department of MedicineMayo ClinicJacksonvilleUSA

Personalised recommendations